share_log

12 Health Care Stocks Moving In Thursday's After-Market Session

Benzinga ·  Oct 25 04:31

Gainers

  • Bionomics (NASDAQ:BNOX) shares rose 48.3% to $0.53 during Thursday's after-market session. The market value of their outstanding shares is at $7.0 million.
  • Lyell Immunopharma (NASDAQ:LYEL) stock moved upwards by 32.92% to $1.45. The company's market cap stands at $370.9 million.
  • Reviva Pharmaceuticals (NASDAQ:RVPH) shares rose 9.64% to $1.25. The market value of their outstanding shares is at $41.3 million.
  • OneMedNet (NASDAQ:ONMD) shares increased by 8.74% to $0.87. The company's market cap stands at $20.7 million.
  • Edwards Lifesciences (NYSE:EW) shares increased by 7.32% to $75.5. The market value of their outstanding shares is at $45.4 billion. As per the press release, Q3 earnings came out today.
  • Impact BioMedical (AMEX:IBO) stock increased by 6.85% to $1.87. The market value of their outstanding shares is at $21.5 million.

Losers

  • DexCom (NASDAQ:DXCM) stock declined by 15.2% to $63.5 during Thursday's after-market session. The company's market cap stands at $25.4 billion. The company's, Q3 earnings came out today.
  • Quince Therapeutics (NASDAQ:QNCX) stock declined by 14.29% to $1.02. The market value of their outstanding shares is at $44.1 million.
  • Universal Health Servs (NYSE:UHS) shares declined by 10.98% to $200.0. The company's market cap stands at $13.3 billion. As per the press release, Q3 earnings came out today.
  • Allakos (NASDAQ:ALLK) stock decreased by 6.65% to $1.11. The market value of their outstanding shares is at $98.7 million.
  • Catheter Precision (AMEX:VTAK) stock fell 6.34% to $0.82. The market value of their outstanding shares is at $2.2 million.
  • Scorpius Holdings (AMEX:SCPX) shares fell 5.55% to $0.71. The market value of their outstanding shares is at $2.2 million.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment